You are here

Sanofi

A busy year ahead for Parkinson’s disease

A busy year ahead for Parkinson’s disease

EP Vantage

Parkinson's Disease

drug development

SAGE Therapeutics

Flag link:

While Life Sciences Industry Remains Strong, Some Big Names Face Layoffs

While Life Sciences Industry Remains Strong, Some Big Names Face Layoffs

BioSpace

Gilead Sciences

Flag link:

Sanofi and GSK target Q4 2021 for COVID-19 vaccine rollout

Sanofi and GSK target Q4 2021 for COVID-19 vaccine rollout

Biopharma Reporter

Flag link:

After setback, Sanofi, GSK take tweaked COVID-19 vaccine into phase 2

After setback, Sanofi, GSK take tweaked COVID-19 vaccine into phase 2

Fierce Biotech

clinical trials

Flag link:

After Pfizer deal, Sanofi offers a hand to Johnson & Johnson for COVID-19 vaccine production

After Pfizer deal, Sanofi offers a hand to Johnson & Johnson for COVID-19 vaccine production

Fierce Pharma

Flag link:

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Fierce Biotech

clinical trial simulation

Flag link:

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

Reuters

Bristol-Myers Squibb

deceptive marketing

Flag link:

Sanofi’s COVID-19 Vaccine With Translate Bio Delayed Until Next Year – Report

Sanofi’s COVID-19 Vaccine With Translate Bio Delayed Until Next Year – Report

Yahoo/SmarterAnalyst

Flag link:

Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

Endpoints

Flag link:

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

Yahoo/Benzinga

advanced basal cell carcinoma

Flag link:

Pharma Sanofi CEO: mRNA is likely the 'go-to' vaccine tech for a pandemic, but the 'bar is high' in other diseases

Pharma Sanofi CEO: mRNA is likely the 'go-to' vaccine tech for a pandemic, but the 'bar is high' in other diseases

Fierce Pharma

Flag link:

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Fierce Biotech

Flag link:

Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?

Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?

Endpoints

Flag link:

Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings

Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings

Endpoints

Parkinson's Disease

drug development

Flag link:

Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production

Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production

Xtalks

drug manufacturing

Flag link:

Mark Your Calendar For February PDUFA Dates

Mark Your Calendar For February PDUFA Dates

Yahoo/Benzinga

Adamas Pharmaceuticals

TG Therapeutics

Flag link:

Go or no go? Oncology decisions ahead for the FDA

Go or no go? Oncology decisions ahead for the FDA

EP Vantage

Bristol-Myers Squibb

TG Therapeutics

Sarepta Therapeutics

Flag link:

Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

BioPharma Dive

drug manufacturing

Flag link:

Paul Hudson faces down French unions in fight to restructure Sanofi

Paul Hudson faces down French unions in fight to restructure Sanofi

Endpoints

Flag link:

AstraZeneca, Sanofi, Eli Lilly sue HHS over 340B opinion

AstraZeneca, Sanofi, Eli Lilly sue HHS over 340B opinion

Beckers Hospital Review

Flag link:

Pages